Literature DB >> 32424585

Development and External Validation of Radiomics Approach for Nuclear Grading in Clear Cell Renal Cell Carcinoma.

Hongyu Zhou1,2,3, Haixia Mao4, Di Dong2,3, Changjie Pan5, Mengjie Fang2,3, Dongsheng Gu2,3, Xueling Liu4, Min Xu4, Shudong Yang6, Jian Zou7, Ruohan Yin5, Hairong Zheng8,9, Jie Tian10,11,12,13, Xiangming Fang14.   

Abstract

BACKGROUND AND
PURPOSE: Nuclear grades of clear cell renal cell carcinoma (ccRCC) are usually confirmed by invasive methods. Radiomics is a quantitative tool that uses non-invasive medical imaging for tumor diagnosis and prognosis. In this study, a radiomics approach was proposed to analyze the association between preoperative computed tomography (CT) images and nuclear grades of ccRCC.
METHODS: Our dataset included 320 ccRCC patients from two centers and was divided into a training set (n = 124), an internal test set (n = 123), and an external test set (n = 73). A radiomic feature set was extracted from unenhanced, corticomedullary phase, and nephrographic phase CT images. The maximizing independent classification information criteria function and recursive feature elimination with cross-validation were used to select effective features. Random forests were used to build a final model for predicting nuclear grades, and area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of radiomic features and models.
RESULTS: The radiomic features from the three CT phases could effectively distinguished the four nuclear grades. A combined model, merging radiomic features and clinical characteristics, obtained good predictive performances in the internal test set (AUC 0.77, 0.75, 0.79, and 0.85 for the four grades, respectively), and performance was further confirmed in the external test set, with AUCs of 0.75, 0.68, and 0.73 (no fourth-level data).
CONCLUSION: The combination of CT radiomic features and clinical characteristics could discriminate the nuclear grades in ccRCC, which may help in assisting treatment decision making.

Entities:  

Mesh:

Year:  2020        PMID: 32424585     DOI: 10.1245/s10434-020-08255-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Identification and validation of novel prognostic markers in Renal Cell Carcinoma.

Authors:  Maj Rabjerg
Journal:  Dan Med J       Date:  2017-10       Impact factor: 1.240

  1 in total
  5 in total

1.  CT-based radiomics stratification of tumor grade and TNM stage of clear cell renal cell carcinoma.

Authors:  Natalie L Demirjian; Bino A Varghese; Steven Y Cen; Darryl H Hwang; Manju Aron; Imran Siddiqui; Brandon K K Fields; Xiaomeng Lei; Felix Y Yap; Marielena Rivas; Sharath S Reddy; Haris Zahoor; Derek H Liu; Mihir Desai; Suhn K Rhie; Inderbir S Gill; Vinay Duddalwar
Journal:  Eur Radiol       Date:  2021-11-10       Impact factor: 5.315

Review 2.  Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.

Authors:  Cyra Y Kang; Samantha E Duarte; Hye Sung Kim; Eugene Kim; Jonghanne Park; Alice Daeun Lee; Yeseul Kim; Leeseul Kim; Sukjoo Cho; Yoojin Oh; Gahyun Gim; Inae Park; Dongyup Lee; Mohamed Abazeed; Yury S Velichko; Young Kwang Chae
Journal:  Oncologist       Date:  2022-06-08       Impact factor: 5.837

3.  Preoperative Predicting the WHO/ISUP Nuclear Grade of Clear Cell Renal Cell Carcinoma by Computed Tomography-Based Radiomics Features.

Authors:  Claudia-Gabriela Moldovanu; Bianca Boca; Andrei Lebovici; Attila Tamas-Szora; Diana Sorina Feier; Nicolae Crisan; Iulia Andras; Mircea Marian Buruian
Journal:  J Pers Med       Date:  2020-12-23

4.  A Reliable Prediction Model for Renal Cell Carcinoma Subtype Based on Radiomic Features from 3D Multiphase Enhanced CT Images.

Authors:  Haijie Zhang; Fu Yin; Menglin Chen; Anqi Qi; Zihao Lai; Liyang Yang; Ge Wen
Journal:  J Oncol       Date:  2021-09-21       Impact factor: 4.375

5.  A CT-Based Radiomics Nomogram Integrated With Clinic-Radiological Features for Preoperatively Predicting WHO/ISUP Grade of Clear Cell Renal Cell Carcinoma.

Authors:  Yingjie Xv; Fajin Lv; Haoming Guo; Zhaojun Liu; Di Luo; Jing Liu; Xin Gou; Weiyang He; Mingzhao Xiao; Yineng Zheng
Journal:  Front Oncol       Date:  2021-12-03       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.